FDA approves KalVista’s Ekterly for hereditary angioedema
The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only oral on-demand …
Post
-
-
J&J eyes prostate cancer label expansion for Akeega
Johnson & Johnson (J&J) has applied to the European Medicines Agency (EMA) to extend the indication of Akeega (niraparib and …
-
DoH and Children’s National Hospital link for cell and gene therapy
The Department of Health – Abu Dhabi (DoH) in the United Arab Emirates (UAE) and US Children’s National Hospital (known …
-
Alembic Pharmaceuticals acquires UTILITY therapeutics
Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya (pivmecillinam 185 mg tablets), a penicillin …
-
CDMO insights podcast series: Our Experience is Your Strength | Episode #1 Formulation
The early stages of formulation development and analytical testing can be some of the most exciting phases of drug development, …
-
Five lessons from biopharma companies’ data transformation journeys
Author: Sebastian Wurst, Director, OpenData Strategy, Europe As global biopharmas expand into new markets, they introduce more systems to handle increasing …
-
Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access …
-
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
AstraZeneca has added another indication to its blockbuster immunotherapy Imfinzi (durvalumab), gaining European approval to treat a type of bladder …
-
Big pharma braces for revenue headwinds as patent expiries loom
One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for …
-
Biocon’s Denosumab biosimilars gain EU marketing authorisation
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). This approval from the European …
-
Brii Biosciences and Joincare sign licence agreement for BRII-693
Brii Biosciences and the Joincare Pharmaceutical Group have signed a licence and technology transfer agreement for BRII-693, a new synthetic …
-
Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of …
-
UK Government reveals 10-year plan for NHS
The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community …
-
BioVersys and Shionogi agree to develop ansamycin leads
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads from …
-
Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of another BCMAxCD3 bispecific …
